Matches in SemOpenAlex for { <https://semopenalex.org/work/W1601207844> ?p ?o ?g. }
- W1601207844 abstract "Background Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disorder that mainly affects the small joints of the hands and feet. Erythropoiesis‐stimulating agents have been used to treat anemia, one of the extra‐articular manifestations of RA. Although anemia is less of a problem now because of the reduction in inflammation due to disease‐modifying antirheumatic drugs (DMARDs), it could still be an issue in countries where DMARDs are not yet accessible. Objectives We assessed the clinical benefits and harms of erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (issue 7 2012), Ovid MEDLINE and Ovid MEDLINE(R) In‐Process & Other Non‐Indexed Citations (1948 to 7 August 2012), OVID EMBASE (1980 to 7 August 2012), LILACS (1982 to 7 August 2012), the Clinical Trials Search Portal of the World Health Organization, reference lists of the retrieved publications and review articles. We did not apply any language restrictions. Selection criteria We included randomized controlled trials (RCTs) in patients aged 16 years or over, with a diagnosis of rheumatoid arthritis affected by anemia. We considered health‐related quality of life, fatigue and safety as the primary outcomes. Data collection and analysis Two authors independently performed trial selection, risk of bias assessment, and data extraction. We estimated difference in means with 95% confidence intervals (CIs) for continuous outcomes. We estimated risk ratios with 95% CIs for binary outcomes. Main results We included three RCTs with a total of 133 participants. All trials compared human recombinant erythropoietin (EPO), for different durations (8, 12 and 52 weeks), versus placebo. All RCTs assessed health‐related quality of life. All trials had high or unclear risk of bias for most domains, and were sponsored by the pharmaceutical industry. Two trials administered EPO by a subcutaneous route while the other used an intravenous route. We decided not to pool results from trials, due to inconsistencies in the reporting of results. Health‐related quality of life: subcutaneous EPO – one trial with 70 patients at 52 weeks showed a statistically significant difference in improvement of patient global assessment (median and interquartile range 3.5 (1.0 to 6.0) compared with placebo 4.5 (2.0 to 7.5) (P = 0.027) on a VAS scale (0 to 10)). The other shorter term trials (12 weeks with subcutaneous EPO and eight weeks with intravenous administration) did not find statistically significant differences between treatment and control groups in health‐related quality of life outcomes. Change in hemoglobin: both trials of subcutaneous EPO showed a statistically significant difference in increasing hemoglobin levels; (i) at 52 weeks (one trial, 70 patients), intervention hemoglobin level (median 134, interquartile range 110 to 158 g/litre) compared with the placebo group level (median 112, interquartile range; 86 to 128 g/litre) (P = 0.0001); (ii) at 12 weeks (one trial, 24 patients) compared with placebo (difference in means 8.00, 95% CI 7.43 to 8.57). Intravenous EPO at eight weeks showed no statistically significant difference in increasing hematocrit level for EPO versus placebo (difference in means 4.69, 95% CI ‐0.17 to 9.55; P = 0.06). Information on withdrawals due to adverse events was not reported in two trials, and one trial found no serious adverse events leading to withdrawals. None of the trials reported withdrawals due to high blood pressure, or to lack of efficacy or to fatigue. Authors' conclusions We found conflicting evidence for erythropoiesis‐stimulating agents to increase quality of life and hemoglobin level by treating anemia in patients with rheumatoid arthritis. However, this conclusion is based on randomized controlled trials with a high risk of bias, and relies on trials assessing human recombinant erythropoietin (EPO). The safety profile of EPO is unclear. Future trials assessing erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis should be conducted by independent researchers and reported according to the CONSORT statements. Trials should be based on Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and The Patient‐Centered Outcomes Research Institute (PCORI) approaches for combining both clinician and patient perspectives." @default.
- W1601207844 created "2016-06-24" @default.
- W1601207844 creator A5044974328 @default.
- W1601207844 creator A5054278670 @default.
- W1601207844 creator A5055841616 @default.
- W1601207844 date "2013-02-28" @default.
- W1601207844 modified "2023-09-27" @default.
- W1601207844 title "Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis" @default.
- W1601207844 cites W1529371040 @default.
- W1601207844 cites W1550247426 @default.
- W1601207844 cites W1701993624 @default.
- W1601207844 cites W1881645841 @default.
- W1601207844 cites W1947346879 @default.
- W1601207844 cites W1969576864 @default.
- W1601207844 cites W1970705686 @default.
- W1601207844 cites W1971260052 @default.
- W1601207844 cites W1972195970 @default.
- W1601207844 cites W1972260676 @default.
- W1601207844 cites W1973672831 @default.
- W1601207844 cites W1973938903 @default.
- W1601207844 cites W1975862779 @default.
- W1601207844 cites W1976133234 @default.
- W1601207844 cites W1981680557 @default.
- W1601207844 cites W1982996857 @default.
- W1601207844 cites W1983973201 @default.
- W1601207844 cites W1986360186 @default.
- W1601207844 cites W1986689454 @default.
- W1601207844 cites W1987460376 @default.
- W1601207844 cites W1995162700 @default.
- W1601207844 cites W2004592026 @default.
- W1601207844 cites W2009326492 @default.
- W1601207844 cites W2010149513 @default.
- W1601207844 cites W2010494541 @default.
- W1601207844 cites W2015610252 @default.
- W1601207844 cites W2019251546 @default.
- W1601207844 cites W2023245037 @default.
- W1601207844 cites W2023286210 @default.
- W1601207844 cites W2025957062 @default.
- W1601207844 cites W2032541700 @default.
- W1601207844 cites W2033262426 @default.
- W1601207844 cites W2035645353 @default.
- W1601207844 cites W2043743565 @default.
- W1601207844 cites W2045027755 @default.
- W1601207844 cites W2045112981 @default.
- W1601207844 cites W2046391772 @default.
- W1601207844 cites W2048462515 @default.
- W1601207844 cites W2049358928 @default.
- W1601207844 cites W2055383116 @default.
- W1601207844 cites W2056316780 @default.
- W1601207844 cites W2056402869 @default.
- W1601207844 cites W2061341347 @default.
- W1601207844 cites W2061697214 @default.
- W1601207844 cites W2063407488 @default.
- W1601207844 cites W2064126141 @default.
- W1601207844 cites W2073271820 @default.
- W1601207844 cites W2074040887 @default.
- W1601207844 cites W2075497845 @default.
- W1601207844 cites W2076841930 @default.
- W1601207844 cites W2083395794 @default.
- W1601207844 cites W2089765165 @default.
- W1601207844 cites W2090132603 @default.
- W1601207844 cites W2090822859 @default.
- W1601207844 cites W2092985139 @default.
- W1601207844 cites W2093043874 @default.
- W1601207844 cites W2093161797 @default.
- W1601207844 cites W2093894133 @default.
- W1601207844 cites W2094710872 @default.
- W1601207844 cites W2104675861 @default.
- W1601207844 cites W2105422073 @default.
- W1601207844 cites W2106176385 @default.
- W1601207844 cites W2106641131 @default.
- W1601207844 cites W2107529798 @default.
- W1601207844 cites W2107900017 @default.
- W1601207844 cites W2109346853 @default.
- W1601207844 cites W2110826367 @default.
- W1601207844 cites W2110996113 @default.
- W1601207844 cites W2111945506 @default.
- W1601207844 cites W2113462770 @default.
- W1601207844 cites W2114771952 @default.
- W1601207844 cites W2119463649 @default.
- W1601207844 cites W2119605658 @default.
- W1601207844 cites W2121871264 @default.
- W1601207844 cites W2125435699 @default.
- W1601207844 cites W2129612306 @default.
- W1601207844 cites W2131817768 @default.
- W1601207844 cites W2135400982 @default.
- W1601207844 cites W2135453000 @default.
- W1601207844 cites W2141982867 @default.
- W1601207844 cites W2144762512 @default.
- W1601207844 cites W2148293748 @default.
- W1601207844 cites W2150250025 @default.
- W1601207844 cites W2152348310 @default.
- W1601207844 cites W2154367023 @default.
- W1601207844 cites W2154396744 @default.
- W1601207844 cites W2159705610 @default.
- W1601207844 cites W2170525451 @default.
- W1601207844 cites W2170790620 @default.
- W1601207844 cites W2280893774 @default.
- W1601207844 cites W2332846410 @default.
- W1601207844 cites W2547933991 @default.